Fulgent Genetics Inc (FLGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -43,820 | -175,239 | 141,923 | 506,239 | 214,310 |
| Depreciation Amortization | 19,378 | 142,466 | 37,429 | 18,600 | 3,819 |
| Income taxes - deferred | -3,736 | 11,466 | -8,280 | -8,188 | -1,775 |
| Accounts receivable | -16,303 | 2,388 | 68,638 | 42,300 | -178,480 |
| Accounts payable and accrued liabilities | 3,066 | -6,896 | -25,339 | -12,206 | 22,617 |
| Other Working Capital | -7,239 | 2,841 | 2,005 | -2,676 | -91,451 |
| Other Operating Activity | 69,714 | 49,977 | 37,144 | -5,492 | 171,588 |
| Operating Cash Flow | $21,060 | $27,003 | $253,520 | $538,577 | $140,628 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -472,415 | -491,914 | -417,982 | -710,490 | -304,440 |
| PPE Investments | -40,002 | -21,432 | -18,363 | -23,749 | -35,122 |
| Net Acquisitions | N/A | -399 | -172,679 | -61,868 | N/A |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -3,971 |
| Sale Of Investment | 454,065 | 552,643 | 372,710 | 269,591 | 17,095 |
| Purchase Sale Intangibles | N/A | N/A | N/A | -32 | 0 |
| Other Investing Activity | 0 | 0 | -25,000 | -20,032 | 0 |
| Investing Cash Flow | $-58,352 | $38,898 | $-261,314 | $-546,548 | $-326,438 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 15,019 |
| Debt Repayment | -1,774 | -4,996 | -1,067 | -11 | 0 |
| Common Stock Issued | 51 | 3 | 31 | 89,561 | 246,294 |
| Common Stock Repurchased | -3,124 | -27,792 | -76,105 | -4,155 | -62 |
| Other Financing Activity | 0 | -15,000 | 0 | 10 | 0 |
| Financing Cash Flow | $-4,847 | $-47,785 | $-77,141 | $85,405 | $261,251 |
| Exchange Rate Effect | -55 | -149 | -453 | 34 | 20 |
| Beginning Cash Position | 97,473 | 79,506 | 164,894 | 87,426 | 11,965 |
| End Cash Position | 55,279 | 97,473 | 79,506 | 164,894 | 87,426 |
| Net Cash Flow | $-42,194 | $17,967 | $-85,388 | $77,468 | $75,461 |
| Free Cash Flow | |||||
| Operating Cash Flow | 21,060 | 27,003 | 253,520 | 538,577 | 140,628 |
| Capital Expenditure | -40,315 | -22,207 | -18,775 | -23,812 | -35,130 |
| Free Cash Flow | -19,255 | 4,796 | 234,745 | 514,765 | 105,498 |